Immunologic Consequences of Blood Transfusion and Their Clinical Manifestations

International Archives of Allergy and Immunology

Volumn 114, Issue 4, 1997, Pages 303-315

  Petranyi G G ^a   Réti, Marienn ^b   Harsényi, Veronika ^c   Szabo J ^c  

^a National Institute of Haematology and Immunology Budapest   (Hungary)

^b Szent Laszlo Hospital   (Hungary)

^c Hungarian National Blood Transfusion Service   (Hungary)

Author keywords

Allosensitization; Blood products; Blood transfusion; Immune regulation; Leukocyte filtration; Transfusion side effects; Viral transmission

Indexed keywords

ALLOANTIGEN; COMPLEMENT; HEAT SHOCK PROTEIN; HLA ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; MEMBRANE ANTIGEN;

ANTIGEN BINDING; AUTOIMMUNITY; BLOOD COMPONENT; BLOOD FILTRATION; BLOOD GROUP; BLOOD TRANSFUSION; CLINICAL IMMUNOLOGY; DRUG THERAPY; FEVER; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENETICS; IMMUNOMODULATION; IMMUNOTHERAPY; KIDNEY TRANSPLANTATION; LYMPHOCYTE; MOLECULAR BIOLOGY; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RECURRENT ABORTION; REVIEW; SENSITIZATION; SYMPTOM;

EID: 0030734274     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000237687     Document Type: Article

References (157)

1. Mollison PL, Engelfriet CP, Contreras M: Blood Transfusion in Clinical Medicinc, cd S, Oxford, Blackwell Scientific Publication, 1988, chap 13, pp 587-637.
2. Lizza C, Myers J, Gindy L: Blood groups: in Petz LD, Swisher SN, Kleinman S, Spence RK, Strauss RG (eds): Clinical Practicc of Transfusion Medicinc, New York, Churchill Livingstone, 19%, pp 71 152.
3. Petz LD, Swisher SN: Immunology and ¡is relation to blood transfusion: in Petz LD, Swisher SN, Kleinman S, Spence RK, Strauss RG (eds): Clinical Practice of Transfusion Medicine, New York, Churchill Livingstone, 1996, pp 33 58.
4. Cecka JM: The HLA system; in Petz LD, Swisher SN, Kleinman S, Spence RK, Strauss RG (eds): Clinical PracticeofTransfusion Medicine, New York, Churchill Livingstone, 1996, pp 153-176.
5. sail Els ACM, Antaro JD, Pool J, Blokland F., Bakkcr A, van Elsen PJ, van Rood JJ, Goulmy li: Immunogcnetics of human minor histocompatibility antigens: Their polymorphism and immunodominance, Immunogcnetics 1992:35: 161-165.
6. Roopenian DC: What are minor histocompatibility loci? A new look at an old question, Immunol Today 1992;13:7-10.
7. Simpson E: Minor histocompatibility antigens, Immunol Letter 1991:29:9-14.
8. Opelz G: HLA antigen sensitization: A problem in graft survival, Transplant Proc 1989:21:39-41.
9. Borlcffs JCC, Neuhaus P, van Rood JJ, Balner H: Platelet transfusions have a positive effect on kidney allograft surv ival in rhesus monkeys and induce virtually no cytotoxic antibodies, Transplant Proc 1983:15:985-987.
10. Von dcm Borne AEG: Diagnosis and therapy of platelet disorders, with an emphasis on transfusion therapy; in Rossi U, Van Akcn WG, Mar-tin-Vega C (eds): Transfusion Medicine in Clinical Practice in the Year 2000, Proccding of the Educational Course of the 4th ISBT Regional (3rd European) Congress, Barcelona, 1993, pp 87 95.
11. McCullough J: Granulocyte transfusion;in Petz LD, Swisher SN, Kleinman S, Spence RK, Strauss RG (eds): Clinical Practicc ofTransfusion Medicine, New York, Churchill Livingstone, 1996, pp 413-432.
12. Paloczi K: The role of cell surface antigens in bone marrow and stem ccll transplantation; in Paloczi K (cd): Clinical Applications of Immu-nophenotypic Analysis, Austin, Landes, 1994, pp 77-103.
13. Grundy HO, Pcltz G, Moore KW, Golbus MS, Jackson LG, Lcbo RV: The polymorphic Fcg rc-ceptor 11 gene maps to human chromosome I q, Immunogcnetics 1989;29:331-339.
14. Edbcrg JC, Redecha PB, Salmon JE, Kimberly RP: Human FcgRIII (CD 16), Isoforms with dis-tict allelic expression, extracellular domains, and membrane linkages on polymorphonuclear and natural killer cells, J Immunol 1989:143: 1642-1649.
15. Ballard L, Scya T, Tcekman J, Lublin DM, Atkinson JP: A polymorphism of the complement regulatory protein MCP (membrane eofactor protein or gp 45-70), J Immunol 1987:138: 3850-3855.
16. Wilton AN, Johnstone RW, McKenzie IFC, Purcell DFJ: Strong association between RFLPand protein polymorphisms for CD46, Immunogcnetics 1992:36:79-85.
17. Russ GR, McLoughney J, Nicholls C, Starr R: Monocyte alloantigcns recognized by dialysis and transplant sera, Transplant Proc 1988:20: 17-19.
18. Jager MJ, Paul LC, Persijn GG, van Leeuwen A, van Rood JJ: Recognition of polymorphic monocyte antigens, Tissue Antigens 1986:27: 15-21.
19. Turman MA, Casali P, Notkins AL, Bach I'll, Platt JL: Polyreactivity and antigen specificity of human xcnoreactive monoclonal and serum natural antibodies, Transplantation 1991:52: 710-717.
20. Awdeh ZL, AlperCA: Inherited structural polymorphism of the fourth component of human complement, Proc Natl Acad Sei 1980:77: 3576-3580.
21. de Cordoba SR, Rubinstein P: Genetic polymorphism of human factor H (b IH), J Immunol 1984:132:1906 1908.
22. Giles CM, Uring-Lambcrt B, Goelz J, Hauptmann G, Fielder AHL, Oilier W, RittnerC, Robson T: Antigenic determinants expressed by human C4 allotypcs;a study of 325 families provides evidence for the structural antigenic model, Immunogenetics 1988:27:442-448.
23. Partanen J, Milner C, Campbell RD, Maki M, Lipsanen V, Koskimies S: HLA-linked heat-shock protein 70 (HSP70-2) gene polymorphism and celiac disease, Tissue Antigens 1993:41:15—19.
24. Klein J: Immunoglobulins and B-cell receptors; in Klein J (cd): Immunology, The Science of Self-Nonsclf Discrimination, New' York, Wiley, 1982, pp 157-254.
25. Shivdasani RA, Haluska FG, Dock NL, Dover JS, Kineke EJ, Anderson KC: Brief report: Graft-versus-host disease associated with transfusion of blood from unrelated HLA-homozy-gous donors, N Engl J Med 1993;328:766-770.
26. Brittingham TE, Chaplin HJ: Febrile transfusion reaction caused by sensitivity to donor leukocytes and platelets, J Am Med Assoc 1957: 165:819-825.
27. Kevy S, Schmidt PJ, McGinnis MH, Workman WG: Febrile, nonhemolytic transfusion reactions and the limited role of leukoagglutinins in their etiology, Transfusion 1962:2:7 16.
28. Perkins HA, Payne R, Ferguson J, Wood M: Nonhemolytic febrile transfusion reactions, Vox Sang 1966:11:578-600
29. de Rie MA, van der Plas-van Dalcn CM, En-gelfrict CP, von dem Borne AEG: The serology of febrile transfusion reactions, Vox Sang 1985; 49 126-134.
30. Menitove JE, McElligott MC, Aster RH: Febrile transfusion reaction: What blood component should be given next? Vox Sang 1982:42:318.
31. Chambers LA, Kruskall MS, Pacini DG, Donovan I.M: Febrile reactions after platelet transfusions: The elTcct of single versus multiple donors, Transfusion 1990;30:219-221.
32. Sirchia G: Clinical experience of white cell reduction in blood components: An overview: in Hogman CF (cd): Leukocyte Depletion of Blood Components, Amsterdam, VU University Press, 1994, pp: 59-75.
33. Muvlle L, Joos M, Wouters E, De Bock R, Pce-tcrmans ME: Increased tumor necrosis factor alpha (TNF-alpha), interleukin I, and interleukin« levels in the plasma of stored platelet concentrates: Relationship between TNF-alpha and II.-6 levels and febrile transfusion reactions, Transfusion 1993:331: 195-199.
34. Stack G, Snyder EL: Cytokine generation in stored platelet concentrates, Transfusion 1994: 34:20-25.
35. Ferrara JLM: The febrile platelet transfusion reaction: A cytokine shower, Transfusion 1995: 35/2:89-90.
36. Muylle L, Peetermans ME: Effect of prestorage leukocyte removal on the cytokine levels in stored platelet concentrates, Vox Sang 1994:66: 14-17.
37. Aye MT, Palmer DS, Giulivi A, Hashemi S: Effect of filtration of platelet concentrates on the accumulation of cytokines and platelet release factors during storage, Transfusion 1995:35 2: 117-124.
38. Slichter SJ: Transfusion and bone marrow transplantation, Transfus Med Rev 1988:2:1 17.
39. Schiffer CA, Lichtenfeld JL, Wiemik PH, Mar-diney MR, Joseph JM: Antibody response in patients with acute nonlymphocytic leukaemia, Cancer 1976:37:2177-2182.
40. Howard JE, Perkins IIA: The natural history of alloimmunisation to platelets, Transfusion 1978: 18:496-503.
41. Pegels JG, Bruynes ECE, Engelfrict CP, Von deni Borne AEGKr: Serological studies in patients on platelet and granulocytc-substitution therapy, Br J Haematol 1982;52:59-68.
42. Murphy MF, Waters AH: Immunological aspects of platelet transfusions, Br J Haematol 1985:60:409-414.
43. Meryman HT, Mincheff MS: Mechanism ofal-loimniunisation to HLA antigens; in Hogman CF (ed): Leukocyte Depletion of Blood Components, Amsterdam, VU University Press, 1994, pp 5-10.
44. Brand A, Claas FIIJ, Gratama JW, Eernissc JG: Icukocyte depleted blood components prevent primary HLA immunisation in the majority of patients receiving multiple blood transfusions; in Brozovic B (ed): The Role of Leukocyte Depletion in Blood Transfusion Practice, Oxford, Blackwell Scientific Publications, 1988, PP 4-7.
45. Radvany KM, Patel KM: Donor-specific transfusions: Donor-recipient HLA compatibility, recipient HLA haplotype, and antibody production, Transfusion 1988:28:137-141.
46. Eernissc K, Brand A: Prevention of platelet refractoriness due to HLA antibodies by administration of leukocyte-poor blood components, Exp Hcmatol 1981:9:77-83.
47. Schiffer CA, Dutcher JP, Aisner J, Hogge D, Wiernik PH, Reilly JP: A randomised trial of leukocyte-depleted platelet transfusion to modify alloimmunisation in patient with leukemia, Blood 1983:62:815-820.
48. Fisher M, Chapman JR, Ting A, Morris PJ: Alloimmunisation to HLA antigens following transfusion with leukocyte-poor and purified platelet suspensions, Vox Sang 1985:49:331-335.
49. Murphy MF, Metcalfe P, Thomas H, Eve J, Ord J, Lister TA, et al: Use of leukocyte-poor blood components and HLA matched platelet donors to prevent HLA alloimmunization, Br JI lacma-tol 1986:62:529-534.
50. Andrew D, Dewailly J, Leberrc C, Quarre MC, Bidet ML, Tardivcl R, et al: Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration, Blood 1988:72:964-969.
51. Sniccinski I, O’Donnell MR, Nowicki B, Hill LR: Prevention of refractoriness and HI.A-al-loimmunization using filtered blood products, Blood 1988:71:1402 -1407.
52. Meryman HT: Transfusion induced alloimmunization and immunosuppression and the effect of leukocyte depletion, Transfus Med Rev 1989:33:180-193.
53. Saarinen UM, Koskimies S, Myllyla G: Systematic use of leukocyte-free blood components to prevent alloimmunisation and platelet refractoriness in multitransfused children with cancer, Vox Sang 1993:65:286-292.
54. Andren G, Klaren J, Dewailly J: Lcuko-deple-lion and prevention of HLA immunization, 4th Regular ISBT Congress, Barcelona, 1993, pp 151-154.
55. Class FI IJ, Smeenk R.IT, Schmidt R, van Steen-bruggc GJ, Ecmisse JG: Alloimmunisation against the MHC antigens after platelet transfusion is due to contaminating leukocytes in the platelet suspensions, J Exp llematol 1981:9: 84-89.
56. Andreu G: UV irradiation: Alternative or supplement to leukodepletion?: in Högman CF (ed): Leukocyte Depletion of Blood Components, Amsterdam, VU University Press, 1994.
57. Fchrman I, Ringdén O, Möller E: Blood transfusions as prctreatmcnt for kidney transplantation: Immunization rate and effect on cellular immune response in vitro, Transplantation 1983:35:339-343.
58. Sanfilippo F, Crawford J, Ness G, Geier S, Bollinger RR: Influence of donor-specific blood transfusions on host cellular immune responsiveness, Transplant Proc 1986:18:692-694.
59. Fox BA, Westrick PW, Nathanson SD: Kinetics of the MLR response following single donor-specific allogeneic blood transfusions, Transplantation 1985:40:275-278.
60. Lagaaij EL, Ruigrok MB, van Rood JJ, Hendriks GFJ, van der Woude F, Weimar W, van llouwclingen HC, Goulmy E: Blood transfusion induced changes in cell-mediated lympho-lysis: To immunize or not to immunize, J Immunol 1991:147:3348-3352.
61. Vandeckerschoe BA, van Brec S, Zhang L, Da-lema G, Zantvoort F, Claas FH.I: Increase of donor-specific cytotoxic T lymphocyte precursors after transfusion, Transplantation 1989:48: 672-675.
62. Claas FH, van Rood JJ: The hyperimmunized patient: From sensitization toward transplantation, Transplant lilt 1988;1:53-57.
63. Claas FH, Lagaaij EL, van Rood JJ: Immunological consequences of blood transfusions, Schweiz Med Wochenschr 1991:121 (suppl 43):70-72.
64. Kotlân B, Gyôdi É, Szabo T, Takàcs K, Tropp-mair J, Petri I, Kaiser G, Kassai M, Huber Ch, Petrànyi GG: Comparative study on alloim-mune reaction induced by leukocyte and platelet transfusion in humans: Characteristic changes of activation markers, gamma interferon- and FcR-blocking antibody production, Hum Immunol 1988:22:19-29.
65. Pocsik É, Mihalik R, Gyodi K, Réti VI, Pàlôczi K, Petrànyi GG, Benczùr M: Activation of lymphocytes after platelet allotransfusion possessing only class I MHC product, Clin Exp Immunol 1990:82:102 107.
66. Pocsik E, Mihalik R, Gyodi É, Kassai M, Mayer K, Pcthô E, Pàlôczi K, Petrànyi GG, Benczùr M: In vivo characteristics of expression of activation antigens on peripheral blood mononuclear cells of alloimmunized volunteers in comparison to in vitro restimulation by PPD and tetanus toxoid in the case of sensitized healthy donors: in Knapp W (ed): Leukocyte Typing, IV White Cell Differentiation Antigens, Oxford, Oxford University Press, 1989, pp 502.
67. Pocsik É, Mihalik R, Réti M, Gyodi É, Pàlôczi K, Mayer K, Kassai M, I lerold M, Huber Ch, Petrànyi G, Benczùr M: Differences in non-MHC restricted cytotoxic activities of human peripheral blood lymphocytes after transfusion with allogeneic leukocytes or platelets possessing class I and or class II MHC molecules, Immunobiology 1990:182:22-31.
68. Van Rood JJ, Claas FHJ: The influence of allogeneic cells on the human T and B cell receptors, Science 1990:248:1388-1393.
69. Vogelsang GB: Transfusion-associated grafl-vcrsus-host disease in lion-immunocompromised host, Transfusion 1990:30/2:101-103.
70. McMilin KD, Johnson RL: HLA homozygosity and the risk of related-donor transfusion-associated graft-versus-host disease, Transfus Med Rev 1993:7/1:37-41.
71. Juji T, Takahashi K, Shibata Y, Idc H, Sakaki-bara T, Ino T, et al: Post-transfusion graft-vcr-sus-host disease in immunocompetent patients after cardiac surgery in Japan, N Engl J Med 1989:321:56.
72. Takahashi K, Juji T, Miyazaki II: Post-transfusion graft-versus-host disease occurring in non-immunosuppressed patients in Japan, Transf Sei 1991; 12:281-289.
73. Ohio H, Yasuda H, Noguchi M, Abe R: Risk of transfusion-associated graft-versus-host disease as a result of directed donations from relatives, Transfusion 1992:32:691-693.
74. Linden JV, Pisciotto P: Transfusion-associated graft-versus-host disease and blood irradiation, Transfus Med Rev 1992:6/2:116-123.
75. Shivdasani RA, Haluska FG, Dock NL, Dover JS, Kineke EJ, Anderson KC, Brief report: Graft versus host disease associated with trans-lusion of blood from unrelated HI.A-homozy-gous donors, N Engl J Med 1993:328:766-770.
76. Imanishi T, Akaza T, Kimura A, Tokunaga K, Gojobori T, Allele and haplotype frequencies for HLA and complement loci in various ethnic groups; in Tsuji K, Aizawa M, Sasazuki T(eds): HLA 1991, Proceedings of the 11th International Histocompatibility Workshop and Conference Yokohama, 1991, London, Oxford University Press, 1992, Vol 1, p 1160.
77. von Fliedner V, Higby D, Kim V: Graft-versus-host disease following blood product transfusion, Am J Med 1982:72:951.
78. Myllyla G: Leukocyte-depleted blood components, 4th Regular ISBT Congress, Barcelona, 1993, pp 148-149.
79. Lcitman SF, Holland PV: Irradiation of blood products, Indications and guidelines, Transfusion 1985:25:293-300.
80. Pisciotto P: Irradiated blood: in Kasprisin DO, Luban NLC (eds): Pediatric Transfusion Medicine, Boca Raton, C'RP Press, 1987, vol 2, pp 1-18.
81. Davey RJ: Effect of irradiation of blood components: in Baldwin ML, et al (eds): Irradiation of Blood Components, Bethcsda, AABB, 1992, pp 51-62.
82. Lcitman SF: Dose, dosimetry, and quality improvement of irradiated blood components, Transfusion 1993;33:447-449.
83. Prince HE: The significance of T lymphocytes in transfusion medicine, Transfus Med Rev 1992:6/1:32-43.
84. Anderson G: Quality assurance of the irradiation process of blood components: in Baldwin ML, et al (eds): Irradiation of Blood Components, Bethcsda, AABB, 1992, pp 63-75.
85. Wieding JU, Venmeycr K, Dittman J, Hidde-manri W, Koehler M: Contamination of fresh-frozen plasma with viable white cells and proliferate stem cells, Transfusion 1994:34:185-186.
86. Bemvil SS, Abdulatiff M, Al-Scdairy S, Sasich F, Shcth K: Fresh frozen plasma contains viable progenitor cells - Should we irradiate? Vox Sang 1994:67:405.
87. Decg HJ, Graham TC, Gerhard-Miller L, Ap-pelbaum FR, Schuening F, Storb R: Prevention of transfusion-induced graft-versus-host disease in dogs by ultraviolet irradiation, Blood 1989;74:2592-2595.
88. Fefer A: Graft-versus-tumor responses: Adoptive cellular therapy in bone marrow transplantation: in Forman SJ, Blume KG, Thomas ED (eds): Bone Marrow Transplantation, Oxford, Blackwell Scientific Publications, 1994, pp 231 241.
89. van Rhee F, Lin F, Cullis JO, Spencer A, Cross NCP, Chase A, el al: Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: The case for giving donor leukocyte transfusions before the onset of hematologic relapse, Blood 1994;83:3377-3383.
90. Tucker J, Murphy MF, Gregory WM, Lim J, Rohatiner AZS, Waters AH, et al: Appparcnt removal of graft-versus-leukaemia effect by the use of leukocyte-poor blood components in patients with acute mveloblastic leukaemia, Br J Haematol 1989;73:572-581.
91. Rebulla P, Pappalcttera M, Barbui T, Cortelez-zi A, Isacchi Ci, Malagnino F, et al: Duration of first remission in leukaemic recipients of leukocyte-poor blood components, BrJ Haematol 1990:75:441-442.
92. Lopez J, Fernandez-Villalta MJ, Gomez-Rcino F, Femandez-Ranada JM: Absence of graft-versus-lcukemia effcct of standard hemothera-py in patients with acute myeloblastic leukemia, Transfusion 1990:30:191-192.
93. Norol F, Parquet N, Kuentz M, Bierling P, C'or-donnier C, Bcaujcan F, ct al: Absence of graft-versus-leukaemia (GVL) effect by leukocytes transfused; A prospective randomized trial in acute myeloid leukaemia (AML) patients, Br J Haematol 1991:78:591-593.
94. Oksancn K, E Ionen K: Impact ofleukocytc-de-pleted blood components on the haematolog-ical recover and prognosis of patients with acute myeloid leukaemia, Br.J Iaematol 1993: 84:639-647.
95. Terasaki PI, Kerisler M, Mickery RM: Prcsen-sitization and kidney transplant failures, Postgrad Med J 1971:47:89-100.
96. Patel R, Merrill JP, Briggs WA: Analysis of results of kidney transplantation: Comparison in recipients w ith and without preformed antileukocyte antibodies, N Engl J Med I97l;285: 275-276.
97. Opelz G, Sengar DPS, Mickey MR, Terasaki PI: Effcct of blood transfusion on subsequent kidney transplants, Transplant Proc 1973:5: 253-259.
98. Terasaki PI: The beneficial transfusion effect on kidney graft survival attributed to clonal deletion, Transplantation 1984:37:119.
99. Singal DP, Joseph S, Ali M, Blajchman MA, Smith EKM, Ludwin D: Antiidiotypic antibodies and suppressor cells in patients receiving pretransplant donor-specific blood transfusions, Transplant Proc 1987:19:3399-3401.
100. Reed E, Hardy M, Bcnvenisty A, Lattes C, Brensilvcr J, McCabe R, et al: Effect of antiidiotypic antibodies to HLA on graft survival in renal allograft recipients, N Engl J Med 1987: 316:1450-1455.
101. Singal DP, Leber B, Hamish DG, Frame B, Joseph S, Blajchman MA: Molecular genetic basis for the antiidiotypic antibody response associated with successful renal allograft survival in humans, Transplant Proc 1991:23: 1059.
102. Leivestad T, Thorsby E: Effects of HLA-ha-ploidcntical blood transfusions on donor-specific immune responsiveness, Transplantation 1984;37:175-181.
103. Quigley RL, Wood KJ, Morris PJ: Transfusion induces blood donor-specific suppressor cells, J Immunol 1989:142:463-470.
104. Fischer E, Lenhard V Seifert P, Kluge A, Jo-hannscn R: Blood transfusion-induced suppression of cellular immunity in man, Hum Immunol 1980:3:187-194.
105. Mickelson EM, Ban MA, Ishioka S, Hansen JA: Monitoring alloimmunc responses in vivo following donor-specific transfusion: Generation of suppressor T cells and alterations in al-loreactive precursor frequencies, Transplant Proc 1985:17:2389-2392.
106. Hutchinson IV: Suppressor T cclls in allogeneic models, Transplantation 1986:41:547-555.
107. Forwell MA, Cocker JE, Peel MG, Tsakiris DJ, Briggs JD, Junor BJR, et al: Correlation between high-molecular-weight Fc-receptor-blocking factors in serum and renal allograft survival, Transplantation 1987:44:227.
108. Padânyi À, Kotlân B, Gyodi F., Rajczy K, Portier F, Pctrânyi GG: Association between long te mi kidney graft survival and the presence of pretransplant cytotoxic anti-HLA and or non-MHC ‘FcgRII blocking" (anti-TLX) alloanti-body, Clin Transpl 1996:10:455-460.
109. Burlingham WJ: What is known about blocking factors in renal allograft recipients, Am J Reprod Immunol Microbiol 1988:16:15-20.
110. MacLeod AM, Power DA, Mason RJ: The transfusion effect in renal transplantation: A possible mechanism of action of transfusion effect in renal transplantation, Lancet 1982:2: 468-470.
111. Van Twuyvcr E, Mooijaart RJD, ten Berge IJM, van der Horst AR, Wilmink JM, Kast WM, el al: Pretransplantation blood transfusion revisited, N Engl J Med 1991:325:1210-1213.
112. de Waal LP, van Twuyvcr E: Blood transfusion and allograft survival: Is mixed chimerism the solution for tolerance induction in clinical transplantation? Immunology 1991:10:417-425.
113. Dzik WH: Mononuclear cell microchimerisni and the immunomodulatory effcct of transfusion: in Hogman CF (ed): Leukocyte Depletion of Blood Components, Amsterdam, UV University Press, 1994, pp 41 50.
114. Lagaaij EL, Hcnnemann IPH, Ruigrok M, de Haan MW, Pcrsijn GG, Termijtelen A, ct al: Effect of onc-HLA-DR-anligen-matched and completely HLA-DR-mismatchcd blood transfusions on survival of heart and kidney allografts, N Engl J Med 1989:321:701 705.
115. Lazda VT, Poliak R, Mozes MF, Barber PL, Jo-nasson O: Evidence that HLA class II disparity is required for the induction of renal allograft enhancement by donor-specific blood transfusions in man, Transplantation 1990:49:1084-1087.
116. Opelz G, Terasaki PI: Poor kidney transplant survival in recipients with frozen-blood transfusions or no transfusion, Lancet 1974:2:696-698.
117. Pcrsijn GG, Cohen B, Lansbergen Q, van Rood JJ: Retrospective and prospective studies on the cffect of blood transfusions in renal transplantation in The Netherlands, Transplantation 1979:28:396-401.
118. Pctranyi GG, Padânyi À, Horuzsko A, Reti M, GyôJi E, Perner F: Mixed lymphocyte culture evidence that pretransplant transfusion with platelets induces FcR and blocking antibody production similar to that induced by leukocyte transfusion, Transplantation 1988;45: 823-824.
119. Horuzsko A, Gyodi É, Réti M, Onody K, Pernor F, Kassay M, ct al: Non-cytotoxic blocking antibodies and suppressor cells induced by donor-specific transfusions in healthy volunteers and potential kidney transplant recipients, Immunol Lett 1990:26:127-130.
120. Horuzsko A, Gyodi É, Réti M, Mayer K, Kas-sai M, Pctranyi G: Selective effect of noncyio-toxic blocking alloantibodies produced after platelet transfusions on MI.C, and mitogen and soluble antigen-induced responses of human lymphocytes, Transplantation 1990:50:497-50.
121. Petrinyi G: Immunological effect of transfusion (in Hungarian), Orvoskepzcs 1994:69: 326-340.
122. Pctranyi G, Padânyi A, Szclcnyi J, Sârniai G, Gyodi E, Fülöp V, et al: The polymorphic human TLX-B/CD46 MCP system and its implications in transplantation and reproduction, EurJ Immunogen 1995:22:147-161.
123. Opelz Ci: The role of 11 LA matching and blood transfusions in the cyclosporine era, Transplant Proc 1989:21:609.
124. Padânyi À, Gyodi É, Horuzsko A, Mihalik R, Pocsik F, Szclényi J, Réti M, Szigetvâri I, Perner F, Kassai M, Schmidt B, Pctranyi G: Temporary tolerence or suppressive regulation induced by non-MHC alloantigens in transplantation and pregnancy: in Gergely J, et al (eds): Progress in Immunology, Budapest, Springer, 1993, voI 8, pp 807-814.
125. Mincheff MS, Mcryman HT, Kapoor V, Alsop P, Wötzel M: Blood transfusion and immuno-modulation: A possible mechanism, Vox Sang 1993:65:18-24.
126. Salvatierra O Jr, Mclzer J, Vincenti F, ctal: Donor-specific blood transfusion versus cyclosporin -The DST story, Transplant Proc 1987: 19:160-166.
127. Shelby J, Marushack MM, Nelson EW: Prostaglandin production and suppressor cell induction in transfusion-induced immune suppression, Transplantation 1987:43:113-116.
128. Klatzmann D, Bensussan A, Gluckman JC, Foucault C, Dausset J, Sasportes M: Blood transfusions suppress lymphocyte reactivity in uremic patients, II, Evidence for soluble suppressor factors, Transplantation 1983:36:337-340.
129. Shcnton BK, Proud G, Smith BM, Taylor RMR: Identification of immunosuppressive factors in plasma following multiple blood transfusions, Transplant Proc 1979; 11:171-174.
130. Stinison Wl I, Strachan AF: Studies on the maternal immune response to placental antigens: Absence of a blocking factor from the blood of abortion-prone women, Br J Obstct Gynaecol 1979;86:41-45.
131. Unander AM, Olding LB: Habitual abortion: Parental sharing of HLA antigens, absencc of maternal blocking antibody, and suppression of maternal lymphocytes, Am J Rcprod Immunol 1983;4:171-178.
132. Singal DP, Butler L, Liao SK, Joseph S: The fetus as an allograft: Evidence for antiidiotypic antibodies induced by pregnancy, Am J Re-prod Immunol 1984;6:145-151.
133. Padanyi A, Gyodi E, Horuzsko A, Reti M, Fii-lop V, Petranyi G: The functional importance of TLX-B alloantigen system in reproductive immunity; in Sasazuki T(cd): HLA 1991, Disease and Reproductive Studies, Oxford, Oxford University Press, 1992, pp 560 561.
134. Beer AI-, Quebbeman JF, Ayers JWT, Haines RF: Major histocompatibility complex antigens, maternal and paternal immune responses, and chronic habitual abortions in humans, Am J Obstet Gvnecol 1981:141:987-999.
135. Rcznikof T-F, Tievant MF, Durieux I, Huchet J, Salmon Ch, Netter A: Recurrent spontaneous abortions, HLA antigen sharing and anti-pater-tial immunity, immunothcrapeutic assay, Re-prod Immunol Matcrno-fetal Relationship 1987;154:187-202.
136. McIntyre JA, Faulk WP, Verhulst SJ, Colliver JA: Human trophoblast-lymphocyte cross-re-active (TLX) antigens define a new alloantigen system, Science 1983:222:1135-1137.
137. Takakuwa K, Kanazawa K, Takeuchi S: Production of blocking antibodies by vaccination with husband's lymphocytes in unexplained recurrent aborters: The role in successful pregnancy, Am J Reprod Immunol 1986:10:1 9.
138. Beer AE, Shekar SS, Quebbeman JF, Zhu X: Paternal and nonpatemal leukocyte immunization in women with recurrent spontaneous abortions: Immune responses and subsequent pregnancy outcome, Rcprod Immunol Mater-no-fetal Relationship 1987; 154:161 178.
139. Unander AM: The role of immunization treatment in preventing recurrent abortion, Transfus Med Rev 1992:6/1:1-16.
140. Coulam CB, Coulam CH: Update on immunotherapy for recurrent pregnancy loss, Am J Reprod Immunol 1992:27:124-127.
141. Gantt CL: Red blood cells for cancer patients, Lancet 1981;2:363.
142. van Aken WG: Does perioperative blood transfusion promote tumor growth? Transfus Med Rev 1989;3:243-252.
143. Blumberg N, Heal JM: Transfusion and host defenses against cancer recurrence and infection, Transfusion 1989:29/3:237-245.
144. Blumberg N, Triulzi D.I, Heal JM: Transfusion induced immunomodulation and its clinical consequences, Transfus Med Rev 1990; 4(suppl I):24-35.
145. Parrott NR, Blood transfusion - Cancer and postoperative infection; in Hogman CF (eds): Leukocyte Depiction of Blood Components, Amsterdam, VU University Press, 1994, pp 87-96.
146. Busch OR, Hop WCJ, van Papendrecht M, Marquet RL, Jeckcl J: Blood transfusions and prognosis in colorectal cancer, N Engl J Med 1993;328:1372-1376.
147. Ames SA, Shelby J, Roberts LK, Nelson EW: Factors in transfusion-related enhanced tumor growth, Transplant Proc 1988:20:1121-1124.
148. Voogt PJ, van de Velde CJ, Brand A, I lennans J, Stijnen T, Blocm R, Leer JW, Zwaveling A, van Rood JJ: Perioperative blood transfusion and cancer prognosis: Different effect of blood transfusion on prognosis of colon and breast cancer patients, Cancer 1987:59:836-843.
149. lamer PI, Francis DM: Blood transfusion and tumor growth, Transplant Proc 1988:20:1108-1111.
150. Huai-Shen Wu, Little AG: Propcrative blood transfusion and cancer recurrence, J Clin Oncol 1988:8:1348-1354.
151. Bordin JO, Heddle NM, Blajchman MA: Biologic effects of leukocytes present in transfused cellular blood products, Blood 1994;84: 1703-1721.
152. Palmer A, Taube D, Welsh K, Bew ick M, Gjor-strup P, Thick M: Removal of anti-HLA antibodies by extracorporeal immunoadsorption to enable renal transplantation, Lancet 1989;1: 10-12.
153. Rawal BD, Davis ER, Busch MP, Vyas GN: Dual reduction in the immunologic and infectious complications of transfusion by filtration/removal of leukocytes from donor blood soon after collection, Transfus Vied Rev 1990; 4(suppl I):36-41.
154. Meryman HT: Transfusion-induced alloimmunization and immunosuppression and the effects of leukocyte depletion, Transfus Vied Rev 1989;3:180-193.
155. Oluwole SF, Chabot J, Pepino P, Reemtsma K, Hardy MA: In vitro immune responsiveness in rats transfused with ultraviolet irradiated do-nor-specific blood, Transplant Proc 1988: 20(suppl I): 131-133.
156. Poljak-Blazi M, Hadzija VI: Role of class I and class II antigens in specific immunosuppression after transfusion of UV-irradiated blood, Transplant Proc 1987:19:4279 -4280.
157. Deeg HJ: Modification of allointeractions after blood transfusion and marrow transplantation by ultraviolet light, Semin Hematol 1992; 29:95-101.